Astellas Pharma (OTCMKTS:ALPMY) Share Price Passes Above 50 Day Moving Average – Here’s What Happened

Astellas Pharma Inc. (OTCMKTS:ALPMY)’s stock price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $11.36 and traded as high as $12.73. Astellas Pharma shares last traded at $12.73, with a volume of 59,907 shares traded.

Analysts Set New Price Targets

A number of research analysts have recently commented on ALPMY shares. Sanford C. Bernstein lowered Astellas Pharma from an “outperform” rating to a “market perform” rating in a report on Tuesday, September 2nd. Zacks Research cut shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. Two equities research analysts have rated the stock with a Hold rating, According to MarketBeat, the stock has a consensus rating of “Hold”.

Astellas Pharma Stock Down 0.5%

The company has a fifty day moving average price of $11.36 and a two-hundred day moving average price of $10.68. The company has a quick ratio of 0.80, a current ratio of 1.03 and a debt-to-equity ratio of 0.20.

Astellas Pharma (OTCMKTS:ALPMY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.20 by $0.10. Astellas Pharma had a net margin of 6.39% and a return on equity of 22.21%. The firm had revenue of $3.45 billion for the quarter, compared to analysts’ expectations of $3.14 billion. Equities analysts anticipate that Astellas Pharma Inc. will post 0.42 earnings per share for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.